Skip to main content
Scientific Reports logoLink to Scientific Reports
. 2018 Jul 24;8:11380. doi: 10.1038/s41598-018-29406-6

Author Correction: Salvianolic acids from antithrombotic Traditional Chinese Medicine Danshen are antagonists of human P2Y1 and P2Y12 receptors

Xuyang Liu 1,2,3,4, Zhan-Guo Gao 5, Yiran Wu 1, Raymond C Stevens 1, Kenneth A Jacobson 5, Suwen Zhao 1,2,
PMCID: PMC6056558  PMID: 30038283

Correction to: Scientific Reports 10.1038/s41598-018-26577-0, published online 24 May 2018

This Article and the accompanying Supplementary Information file contain errors.

In Figure 2, the wrong µM symbol was used. The correct Figure 2 appears below as Figure 1.

Figure 1.

Figure 1

Radioligand binding assays and functional assays showed that SAA and SAC can bind and antagonize both P2Y1 and P2Y12 receptors, while SAB can bind and antagonize only the P2Y12 receptor. (a) Displacement curves of SAA, SAB and SAC against [3H]2MeSADP binding to the P2Y12 receptor. (b) Functional antagonism by SAA of 2MeSADP-induced inhibition of foskolin-stimulated cAMP accumulation in U2OS cells expressing the P2Y12 receptor. (c) Schild plots of the antagonism of SAA, SAB and SAC at the P2Y12 receptors. (d) Displacement curves of SAA, SAB and SAC against [3H]2MeSADP binding to the P2Y1 receptor. (e) 2MeSADPinduced IP-1 accumulation in U2OS cells expressing the P2Y1 receptor (compared to MRS2500). (f) Schild plots of antagonism by SAA and SAC at the P2Y1 receptor. Results are expressed as mean ± SEM. The Ki values from binding experiments and KB values from Schild analyses of functional antagonism by SAA, SAB and SAC are listed in the text and are from at least three independent experiments. MRS, MRS2500; SAR, SAR216471.

In the Supplementary Information file, the title of Table S1 is incorrectly given as ‘SAA, SAB and SAC are not promiscuously binding compounds’. The correct Table S1 appears below as Table 1.

Table 1.

Targets used in the off-target activities tested by the PDSP.

# Protein name # Protein name
1 5-HT1A 24 D3
2 5-HT1B 25 D4
3 5-HT1D 26 D5
4 5-HT1E 27 GABAA
5 5-HT2A 28 H1
6 5-HT2B 29 H2
7 5-HT2C 30 H3
8 5-HT3 31 H4
9 5-HT5A 32 M1
10 5-HT6 33 M2
11 5-HT7 34 M3
12 α1A 35 M4
13 α1B 36 M5
14 α1D 37 δ-opioid
15 α2A 38 κ-opioid
16 α2B 39 μ-opioid
17 α2C 40 σ1
18 β1 41 σ2
19 β2 42 DAT
20 β3 43 NET
21 BZP rat brain site 44 SERT
22 D1 45 TSPO
23 D2

Finally, in the Supplementary Information file, there is a typographical error in Figure S4 and its accompanying legend where ‘Epinenohrineon’ should read ‘Epinephrine’. The correct Figure S4 appears below as Figure 2.

Figure 2.

Figure 2

The functional activity of SAB on the adrenergic α1B receptor were tested by FLIPR assays. SAB did not show agonist activity on α1B, epinephrine is a control agonist (EC50 29.8 nM) (a). SAB did not show antagonist activity on α1B, WB4104 is a control antagonist (IC50 4.51 nM) (b).


Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES